Category Archives: whatsnew

Rapid insights on clinical impact of ASCO – Integration of new treatment regimens in CLL

After every major conference, MDoutlook provides valuable insights on the impact of new data presented. In our 3rd OncoPoll™ study following the 2019 ASCO conference, we looked at the oral presentations in CLL and researched how US and EU5 oncologists evaluated them.

Click to enlarge

Even with these CLL presentations being on the last day of ASCO, the awareness and enthusiasm for the use of Venetoclax + Obinutuzumab, Acalabrutinib + Obinutuzumab, and the CD19-targeted CAR-T cell product Lisocabtagene Maraleucel does not seem to be dampened. In our full report, we examine how the efficacy and safety & tolerability profiles of each of these agents are viewed in relation to currently available treatment options and how these regimens will be integrated into clinical practice. As can be seen from the data excerpt, there is good reason to assume that the new regimens will be making quite an impact throughout the treatment process.

Click here to get a full copy of our complimentary MDoutlook OncoPoll report

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community – read our blog on this topic on their site.

Last week, we published our post-ASCO OncoPolls on early advanced prostate cancer (nmCRPC and mHSPC) and on novel targeted agents in mNSCLC.

If you need pre- and post-meeting insights on specific topics or data presentations, or other precision intelligence in your focus area, we are ready to discuss.

Rapid insights on clinical impact of ASCO – Novel Targeted Agents for mNSCLC

After every major conference, MDoutlook provides valuable insights on the impact of new data presented. In our 2nd OncoPoll™ study following the 2019 ASCO conference, we researched what US and EU5 oncologists thought about a number of new agents being developed that target specific driver mutations in small populations of metastatic NSCLC patients (among other cancer types).

Click to enlarge

The awareness of these agents is already at a moderate level, higher than what one would normally expect for agents only in Phase 1 and/or Phase 2 clinical trials and broader than just the 40% of respondents who attended the Oral Abstract session at ASCO (see below). In our full report, we examine how the efficacy and safety & tolerability profiles of each of these agents are viewed in relation to currently available treatment options and even dive a little into how these agents are currently compared with each other.

Click here to get a full copy of our complimentary MDoutlook OncoPoll report.

Click to enlarge

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community – read our blog on this topic on their site. We just published our post-ASCO OncoPoll on prostate cancer and our 3rd post-ASCO reports on CLL will be available very soon.

If you need pre- and post-meeting insights on specific topics or data presentations, or other precision intelligence in your focus area, we are ready to discuss.

Rapid insights on clinical impact of ASCO – What will happen in nmCRPC and mHSPC

After every major conference, MDoutlook provides valuable insights on the impact of new data presented. At the 2019 ASCO conference, prostate cancer was one of the hottest areas, and our 1st independent OncoPoll™ study researched how clinicians will be treating the non-metastatic castration-resistant and the metastatic hormone-sensitive prostate cancer (nmCRPC and mHSPC) populations based on the new data presented. The impact of ASCO is far and wide, so in this analysis, we compared how oncologists and urologists in the US and EU5 will be integrating the information into their clinical practices.

post ASCO nmCRPC mHSPC clinical insights MDoutlook

Click to enlarge

All 3 of the 2nd generation anti-androgens discussed during ASCO are seen as more efficacious than currently available treatment options (see figure). But how does this evaluation differ between oncologists and urologists in the US and EU5? Does this positive view extend to the safety profiles? Most importantly, how will these views translate into actual clinical decisions?

Click here to get a full copy of our complimentary MDoutlook OncoPoll report.

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community –read our blog on this topic on their site. Be on the lookout for our additional post-ASCO reports on CLL and NSCLC coming soon.

If you need pre- and post-meeting insights on specific topics or data presentations, or other precision intelligence in your focus area, we are ready to discuss.

Redefining engagement with ThoughtLeaders

Identifying the right expert at the right time is often a challenge for many life sciences companies and their agencies. What if there would be a short-cut (with no compromises!) to gain precision engagement with ThoughtLeaders and related treaters? At MDoutlook, we help you tap into the expertise of over 12,000 oncology ThoughtLeaders and 110,000 qualified oncology treaters from over 120 countries.

Precision ThoughtLeader identification and mapping

ThoughtLeader Professional Network - NeuroEndocrine Tumors

Click to enlarge

Our intuitive dashboard gives clients direct access to our MDoutlook ThoughtLeader Attribute Dial™. Driven by our propriety technology and transparent algorithms, clients can manipulate the information to get access to different data sets and results based on changing inputs to match their business needs.

Our unique peer nomination process is further helping clients to identify ThoughtLeaders that are highly regarded by their peers, especially those with more influences or those beyond the top 50. Obtaining this information is easy, and our dashboard enables clients to have all information in one place at their fingertips.

Patient Volume in Select GI Cancers - ThoughtLeaders vs Community

Click to enlarge

Our infographics allow clients to spot connections between different ThoughtLeaders and uncover early adopters for specific cancer treatments. This is particularly impactful when estimating treatment volumes and identify high-volume treaters for a specific cancer.

For one of our clients, we performed an analysis of nearly 1,300 U.S. physician-reported patient volumes in specific GI tumor types, leading to interesting insights. Academic ThoughtLeaders, on average, saw 20% more patients than other community-based ThoughtLeaders.
This also settles an often-asked question if they are too busy in their expert activities to see patients!

Providing support for all your activities

Whether you are engaging with ThoughtLeaders digitally, personally or on the phone, we support you on your knowledge journey. We provide expert insights and ThoughtLeader identification that will make your advisory councils, expert calls, congresses, and virtual engagements a success! At MDoutlook, we help clients to leverage ThoughtLeaders throughout the commercialization lifecycle of a compound and maximize both opportunities and revenues.

We are passionate about our precision intelligence offering and provide you with rapid and actionable answers to all your business questions. All our solutions are scalable to fit your needs & budgets, including integration with legacy systems.

Let´s discuss how to make your ThoughtLeader engagements more targeted by utilizing our precision insights. Contact us today at [email protected] or call at +1 404.496.4136 to find out how we can help you to make the most of your ThoughtLeader interactions.

Conference data presentation impact

With the deluge of scientific data presentations at a conference, it is very competitive for life science companies to break through the noise and assess impact. By evaluating whether announcements change oncologists’ behavior, we can estimate how a data presentation influences their future treatment decisions and clinical practice.

Clients often find themselves in a situation where they need to quickly understand the implications of their own and their competitors’ conference data announcements. One of our clients needed a quick read on their data presentation vs. competitive activity at a scientific congress to assess the impact on current treatments and preference shifts in treatment decisions. We provided timely actionable recommendations through post-conference research to guide their future commercial activities. Conference channel impact
During this assignment, we were able to demonstrate that both academic and community oncologists consider educational sessions run by conference committees (e.g. ESMO) to be more credible than industry-sponsored symposia. This research highlighted opportunities for future engagement and impact measurement of data presentations.

Be the first to know!

For another client, we recruited 500 cancer treaters from over 30 countries within a week of a conference via our agile ONCpulse™ research service. Access to timely precision intelligence provides clients the confidence to react quickly to our insights, and often, we are the first to offer in-depth results after a congress. If you want to speed up your congress research and be the first to know, we should meet.

Client feedback

“Rapid results allowed us to adapt our commercialization plans for the following year and assess the success of our own data announcements. This is very useful for us in light of next years’ planning”.
Brand Director Oncology, Major Pharmaceutical Company.

Conference Research Specialists

Are you currently facing the challenge of measuring the impact of your scientific data presentation? At MDoutlook, we make this process easier for you. With over a decade of experience and more than 130 conference projects completed, we have helped clients gauge their activity impact by enabling access and engagement opportunities with treaters, experts, and ThoughtLeaders in oncology in/around many major conferences (such as ASCO, ESMO, ASH, SABCS, EHA, IASLC, etc.). If you require rapid quantitative and/or qualitative insights or an advisory board, MDoutlook has a solution for you:

  • ONCpulse™ 10-15mins: designed to gain timely marketplace feedback on a single topic
  • ONCpulse™ 20-25mins: designed to probe a narrow range of specific issues deeply.
  • ONCpulse™ qual: accessing treaters and experts from the world’s largest verified community in oncology.
  • ThoughtLeader identification, mapping and engagement.

Are you planning to present new scientific data at an upcoming conference? Meet us!

We will be at:

  • ASCO annual meeting (May 31 – June 4) in Chicago at booth 5041.
  • European Hematology Association annual meeting (June 13 – 17) in Amsterdam.

Join us for a cup of coffee / tea and a meaningful chat.

Rare cancers prominent ahead of the conference season

Rare cancers feature more prominently at this year’s conference season, and ASCO has named “Progress in Treating Rare Cancers” as their advance of the year. We are especially poised to gauge the reactions of oncologists to the new developments in rare cancers and understanding standard treatment practices if they exist in these challenging diseases. Helping clients to better understand rare cancer market dynamics and particularly conference research is core to our offering.

The recognition of rare cancers by ASCO also resonates with our experience in delivering precision insights to our clients. We have observed an increased interest through our work in these cancers and believe that advancements in areas such as precision medicine are redefining what makes specific cancers rare or common. Together with Biomarkers (click here for Biomarkers article), oncologists have more and new tools at their disposal as sadly the treatment success of rare cancers often lacks behind more common cancers.

At MDoutlook we help clients to overcome these uncertainties in knowledge through access to the world’s largest community of treaters and experts in oncology. Over the past years, our precision intelligence has successfully informed commercialization strategies of numerous compounds at different stages in the product lifecycle.Many of these projects successfully delivered actionable results through our agile ONCpulseTM service and have included examples such as:

  • A recent rush project for a client who needed us to interview over 30 oncologists specializing in a rare Head & Neck cancer area with specific focus on the second line treatment to gain rapid time-sensitive knowledge for their business
  • For another client, we successfully engaged 10 melanoma experts to understand the current diagnosis and management of uveal melanoma, and how to better organize their pivotal clinical trial.

We are in a unique position to reach over 120,000MDoutlook Cancer Treater Universe cancer treaters and experts globally and improve your commercial strategy or simply provide a deeper understanding of rare cancers. Are you interested in similar insights? We invite you to set-up a meeting with us to introduce you to our offering.

We will be at the ASCO annual meeting (May 31 – June 4) in Chicago and look forward to welcoming you there. If you are unable to meet at ASCO, we will be delighted to meet you at the European Hematology Association annual meeting (June 13 – 17) in Amsterdam.

For further discussion or to arrange a meeting at your convenience, please contact [email protected] or call +1 404.496.4136.

 

Join our fast growing team

MDoutlook is continuing its fast growth path. To support our growth, and overall client services and experience, we are keen to add a Manager, Strategic Development to our team at our headquarters in greater Atlanta.

Playing a vital supportive role initially within our business, we look to expand the role quickly to take on greater responsibility within our strategic development team and be exposed to working across our business and with clients. The ideal candidate will be dynamic, energetic and hungry for success. Learn more about the Manager Strategic Development May 2019 here.

If you are interested and qualify for this exciting and demanding position in a great work environment, submit your resume and cover letter directly to our Human Resources group. Solicitation by recruiters will not be considered.

Biomarkers are valued but 1 in 3 oncologists want improvement

Biomarkers are embraced by oncologists as an important tool in their arsenal to treat cancer. They enable a more personalized approach to treatment by identifying patients who are likely to respond to specific immunotherapies and yet oncologists want pharma to do more.

In our 2019 Leadership study, we asked oncologists to reveal their most wanted areas for improvement in ImmunoOncology (IO) where pharma companies should focus their efforts. Their priority list revealed, 1 in 3 oncologists wanted better patient selection through biomarkers. This was among the top 3 priorities with financial impact and access to IO therapies. Our analysis revealed that 35% of European based oncologists want pharma to improve biomarkers compared to 29% of US based colleagues.

Oncologists want to improve patient selection through biomarkers

Click on image to enlarge

While IO therapies can offer tremendous improvement for patients, their response rate to a specific tumor can be as low as 20-30%. The individual gene activity within a cancer is an important cause underlying these varied responses. Certain genes in progressing tumors are activated by immunotherapy and this activity can dampen the immune cell response. We are now seeing combination therapies (using two different IO therapies) entering clinical practice with leading oncologists, and genetic profiling will become even more important in aiding the usage of combining different IO therapies. Oncologist intent to utilize and actual usage of genetic profiling is corroborated in many onco-diagnostics focused MDoutlook research.

Given the benefits of genomic profiling, the MDoutlook team is not surprised that specialized companies such as Foundation Medicine (FMI) have attracted the attention of oncology heavy weights such as Roche. In 2018, Roche completed its acquisition of FMI and is now using their technology to identify molecular alterations in a patient’s cancer. In patients with a high level of mutations, they may only need one IO drug while those with lower levels get a combination therapy. We have extensively studied the area of companion diagnostics and expect more integration beyond the ubiquitous licensing arrangements.

These improved predictions can also help oncologists to adjust their treatment approach and ultimately improve outcomes for patients. Based on late 2018 research with leading oncologists, we expect significant research and developments with respect to combining immune-oncology drugs in relevant patients to boost overall and continued response. Biomarkers are highly valued by oncologists and together with clinical factors (overall survival, quality of life), label and availability of biomarkers have the greatest impact on IO treatment selection.

Click on image to enlarge

Click on image to enlarge

This showcases an opportunity for pharma and represents one of many areas where MDoutlook offer significant research experience through targeted conference research and use of ONCpulse in accessing the world’s largest community of oncologists and experts.

As a trusted partner in oncology, MDoutlook is uniquely placed to help you with precision intelligence and ThoughtLeader engagement ahead of the conference season. Let’s take your next step together.

We look forward to meeting you at the American Society of Clinical Oncology (ASCO) annual meeting (May 31 – June 4) in Chicago and the European Hematology Association (EHA) annual meeting (June 13 – 17) in Amsterdam.

For further discussion or to arrange a meeting, please contact [email protected] or call +1 404.496.4136.

If you wish to be included in the distribution of the 2019 Leadership study, please click here.

Oncologists have no clear leader in pharma engagement solutions

Oncologists have no clear leader when asked about the supportive services and tools provided to them by pharmaceutical companies. Our 2019 Leadership study in ImmunoOncology (IO) explored oncologists’ views across multiple engagement channels ranging from digital support solutions (e.g. apps) to more traditional activities such as educational learning.

HealthCare Provider (HCP) engagement profits from activities that are collaborative in their nature. Providing educational support to both staff and oncologists was appreciated by the surveyed oncologists and contributes to their perception of corporate leadership.

While there was no overall leader in HCP engagement, BMS, Merck and Roche formed the top three companies in our survey, yet collectively not even reaching the 50% mark of all responses.

Oncologists have no clear leader in professional solutions

Click to enlarge image

Similar to our findings in patient support programs, over a quarter of oncologists selected “None” tying it in pole position with BMS (26%). This suggests poor awareness, choice or possibly some dissatisfaction with HCP engagement activities offered by pharmaceutical companies.

To be successful, firms need to provide differentiated solutions that are pertinent to oncologists, offering value and optimization in their work with patients.

Utilizing multiple activities to support the varying needs of oncologists can increase customer interactions and these can be tailored using specialized functions such as medical science liaison (MSL). Given growth of different treatment options in oncology, MSLs are viewed favorably as a trusted resource for unbiased, non-promotional information about treatments.

Our latest findings are a timely input as most companies start their brand planning activities across marketing, medical affairs and other teams to drive successful leadership in the eyes of oncologists.

About the study

The 2019 Leadership Study was conducted with 100 oncologists across US and EU using MDoutlook’s proprietary ONCpulse™ service.

The research objectives were to:

  • Define the meaning of “corporate leadership” to the oncology community
  • Reveal the leaders in oncology and IO and to compare / contrast how companies are evaluated by oncologists
  • Assess current drivers & barriers to IO treatment use and identify what oncologists would like to see improved by corporate leaders in the IO space

Please contact us if you wish to be included in the distribution of the study.

Value of medicines is number one concern for oncologists

Financial impact and affordability of medicines is the number one concern for oncologists in our 2019 Leadership research in ImmunoOncology. Oncologists were asked to choose their top three areas (from a list of fourteen attributes) for corporate leaders to improve most over the next few years.Most Wanted Areas of Improvement for Corporate Leaders in ImmunoOncology - Financial impact

The sentiment is especially pronounced in the United States where almost half (47%) of the surveyed oncologists worry about the financial impact of oncology medications on the healthcare system and patients. In Europe, the concerns are also shared by a large group of oncologists (37%), and equally viewed as the most concerning aspect affecting corporate leadership moving forward. This coincides with the debate on the value of medicines picking up speed on both continents, and in Europe, more regulators and payors are working together on joint HTA assessments and cross-border purchasing (e.g. BeNeLuxA initiative).

While financial considerations do not materially influence treatment decisions of oncologists, the rising cost of medications is an ever-present worry. The surveyed oncologists fear insufficient value may have a toxic financial effect on the overall healthcare system.

Earlier and accelerated access

Oncologists in our research would like to see better and earlier access to innovative treatments for their patients.

In line with our findings from last week, MDoutlook - Oncologist Views on Areas of Improvement in Corporate Leadership patient support programs play an important role in making a difference for patients. Aligning your patient support program with the needs of healthcare professionals while further help to alleviate widely held concerns of “financial toxicity”. Communications and marketing functions also need to improve their messages and materials to better communicate value – see our detailed analysis to the right.
Follow our future releases to find out more about better stakeholder management and engagement using digital tools.

Key takeaways:

  • Value of cancer medicines is primary concern for oncologists
  • Early access schemes do make a difference to patients
  • Align patient support programs with value messaging

About the study

The 2019 Leadership Study was conducted with 100 oncologists across US and EU using MDoutlook’s proprietary ONCpulse™ service.

The research objectives were to:

  • Define the meaning of “corporate leadership” to the oncology community
  • Reveal the leaders in oncology and ImmunoOncology (IO) and to compare / contrast how companies are evaluated by oncologists
  • Assess current drivers & barriers to ImmunoOncology treatment use and identify what oncologists would like to see improved by corporate leaders in the IO space

Please contact us if you wish to be included in the distribution of the study.

Click on image to enlarge